Pimera Therapeutics Announces Grant Award from Medical Research Future Fund (MRFF) for Expansion of Phase 1a/b Study of PMR-116 for MYC-driven Cancers
-Study will be run in Australia by the ...
Pimera Therapeutics to Present at the January 2023 Biotech Showcase in San Francisco
SAN DIEGO, Dec. 7, 2022 /PRNewswire/ -- Pimera ...
Pimera Therapeutics Announces Oral Presentation on PMR-116 at the American Association for Cancer Research (AACR) Annual Meeting 2022
San Diego, CA, March 9, 2022 -- Pimera ...
Pimera Therapeutics Awarded Grant by US Department of Defense to Evaluate PMR-116, a Novel Inhibitor of RNA Polymerase I (Pol I) Transcription, in Patients with Prostate Cancer
-Grant will support clinical studies in MYC overexpressing ...